Preview

Онкоурология

Расширенный поиск

Лечение ранних (I, IIA/B) стадий герминогенных опухолей яичка

https://doi.org/10.17650/1726-9776-2006-2-4-53-58

Полный текст:

Об авторах

А. А. Трякин
ГУ РОНЦ им. Н.Н. Блохина РАМН
Россия


А. А. Буланов
ГУ РОНЦ им. Н.Н. Блохина РАМН
Россия


С. А. Тюляндин
ГУ РОНЦ им. Н.Н. Блохина РАМН
Россия


Список литературы

1. Аксель Е.М., Трапезников Н.Н. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 1999 г. М., 2001.

2. Альмяшев А.З., Кулаев М.Т., Бегоулов И.В. и др. Клиника, диагностика и лечение злокачественных опухолей яичка. Методические указания для врачей и студентов. Саранск, 2001.

3. Мерабишвили В.М. Выживаемость онкологических больных. СПб., ООО «Фирма Коста», 2006.

4. Heidenreich A., Weissbach L., Höltl W. et al. German Testicular Cancer Study Group. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001;166:2161–5.

5. Warde P., Specht L., Horwich A. et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448–52.

6. Travis L.B., Curtis R.E., Storm H. et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–39.

7. Aparicio J., Garcia del Muro X., Maroto P. et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003;14(6):867–72.

8. Oliver R.T., Mason M., von der Masse H. et al. on behalf of the MRC Testis Tumour Group and the EORTC GU Group. A randomized comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. Proc Am Soc Clin Oncol 2004;23, 385; Abstr. 4517.

9. Calvert A.H., Newell D.R., Gumbrell L.A. et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56.

10. Spermon J.R., Roeleveld T.A., van der Poel H.G. et al. Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. Urology 2002;59:923–9.

11. Read G., Stenning S.P., Cullem M.H. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992;10:1762–8.

12. Albers P., Siener R., Kliesch S. et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial. J Clin Oncol 2003;21:1505–12.

13. Klepp O., Dahl O., Flodgren P. et al. Risk-adapted treatment of clinical stage I non-seminoma testis cancer. Eur J Cancer 1997;33:1038–44.

14. Read G., Stenning S.P., Cullen M.H. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:1762–8.

15. Hartmann J.T., Albrecht C., Schmoll H.J. et al. Long term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 1999;80:801–7.

16. Travis L.B., Curtis R.E., Storm H. et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–39.

17. Link R.E., Allaf M.E., Pili R., Kavoussi L.R. Modeling the Cost of Management Options for Stage I Nonseminomatous Germ Cell Tumors: A Decision Tree Analysis. J Clin Oncol 2005,23:5762–73.

18. Classen J., Schmidberger H., Meisner C. et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003;21:1101–6.

19. Fossa S.D., Horwich A. Current status of chemotherapy in advanced seminoma. Eur J Cancer 1997;33(2):181–3.

20. Albers P., Weinknecht S., Krege S. et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors – results of a prospective multicenter trial of the GTCSG. J Urol 2002;167(Suppl):172. Abstr. 690.

21. De Santis M., Bokemeyer C., Becherer A. et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740–4.

22. Stephenson A., Bosl G., Bajorin D. et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 2005;174:557–60.

23. Weissbach L., Bussar-Maatz R., Flechtner H. et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000;37:582–94.

24. Fizazi K., Tjulandin S., Salvioni R. et al. Viable malignant cells after primary chemotherapy for disseminated nonseminatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy – results from an international study. J Clin Oncol 2001;19:2647–7.


Для цитирования:


Трякин А.А., Буланов А.А., Тюляндин С.А. Лечение ранних (I, IIA/B) стадий герминогенных опухолей яичка. Онкоурология. 2006;2(4):53-58. https://doi.org/10.17650/1726-9776-2006-2-4-53-58

For citation:


Tryakin A.A., Bulanov A.A., Tyulyandin S.A. Treatment of early (I, IIA/B) stages of germinomas of the testis. Cancer Urology. 2006;2(4):53-58. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-4-53-58

Просмотров: 57


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X